Bayer (ETR:BAYN) Stock Upgrade
Bankhaus Lampe KG upgraded shares of Bayer (ETR:BAYN) to a solid Buy rating in analysts note shared with investors and clients on 17 December. Analysts currently have a EUR 149.00 Estimated Target Price set on the stock. This Estimated Target Price means a possible upside of 30.82% from the last close price of the stock.
From a total of 19 analysts covering Bayer (ETR:BAYN) stock, 10 rate it a ”Buy”, 0 a “Sell”, and 9 a ”Hold”. This means that 53% of the ratings are positive. The highest target price is €160 while the lowest target price is €121. The mean of all analyst targets is €141.69 with a 24.29% above today’s (€114) stock price. Bayer was the topic of 56 analyst reports since July 22, 2015 according to the firm StockzIntelligence Inc. Independent Research upgraded shares on December 11 to “Buy” rating. Bankhaus Lampe upgraded shares to “Buy” rating and €149 target share price in a report from a December 3. Equinet maintained BAYN stock in a recent report from December 10 with “Neutral” rating. Deutsche Bank upgraded the rating on December 1. Deutsche Bank has a “Buy” rating and a €155 price target on shares. Finally, Jefferies maintained the stock with “Hold” rating in a report issued on a December 8.
The stock increased 0.53% or EUR 0.6 on December 16, striking EUR 114. Approximately 1.79M shares of stock traded hands. Bayer AG (ETR:BAYN) has 0.00% since May 20, 2015 and is . It has outperformed by 2.62% the S&P500.
Bayer AG is a strategic management holding company. The company has a market cap of 91.32 billion EUR. The Company’s business are organized into three subgroups: Bayer HealthCare, Bayer CropScience and Bayer MaterialScience, supported by the service companies Bayer Business Services, Bayer Technology Services and Currenta. It has 25.88 P/E ratio. Bayer HealthCare researches, develops, makes and markets products to improve the health of people and animals.